TEVA
NYSETeva Pharmaceutical Industries Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$33.08-0.21 (-0.63%)
01:30 PM03:30 PM
News · 26 weeks101+200%
2025-12-142026-06-07
Mix4790d
- Insider27(57%)
- Other12(26%)
- SEC Filings5(11%)
- Earnings3(6%)
Latest news
25 items- INSIDERDirector Barer Sol J converted options into 21,739 units of Ordinary Shares, increasing direct ownership by 5% to 448,011 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Lichtenstein Chen converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 302% to 19,296 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Crane Rosemary A converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 13% to 127,739 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Elstein Amir converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 0.69% to 2,118,455 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Lieberman Gerald M converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 13% to 130,149 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Nisen Perry converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 14% to 119,807 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Satchi-Fainaro Ronit converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 15% to 112,401 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Zaks Tal Zvi converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 25% to 73,264 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Mignone Roberto converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 14% to 119,807 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERPresident and CEO Francis Richard D converted options into 13,043 units of Ordinary Shares and sold $211,356 worth of Ordinary Shares (6,153 units at $34.35) as part of a pre-agreed trading plan, increasing direct ownership by 0.59% to 1,177,529 units (SEC Form 4) (tax liability)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRTeva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and CareNew analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led to reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all participants, which were associated with improved activities of daily living.Further data from the 3-year RIM-TD study reinforces the importance of sustained treatment, showing >50% of patients achieve a clinically meaningful response to AUSTEDO by week 15, with additional patients achieving response with continued treatment.The comprehensive data package presented at Psych Congress Elevate advances clinical understanding of TD from diagnosis to long-term management, underscoring Teva's commitment to improving outcomes
- PRTeva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease ChoreaNew real-world survey data reveal the daily impact of Huntington's disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of caregivers noting impact on their own daily lives.2Following treatment with AUSTEDO or AUSTEDO XR, most patients (60-71%) reported improvement across multiple quality of life domains as a result of their improved movements.1 As a result of the patient's reduced chorea impact, most caregivers reported less impact to their daily lives.2These real-world findings reinforce Teva's commitment to advancing innovative treatment options that improve the lives of individuals living with HD chorea and their car
- INSIDEREVP, Global Operations Shields Matthew converted options into 16,195 units of Ordinary Shares and sold $532,330 worth of Ordinary Shares (16,195 units at $32.87) as part of a pre-agreed trading plan (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRTeva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®AHZANTIVE® (aflibercept) is an EMA-approved biosimilar to Eylea® (aflibercept) with demonstrated similarity in efficacy, safety and immunogenicity to the reference product The launch expands Teva's biosimilars portfolio and presence in ophthalmology, in line with the Company's Pivot to Growth strategy Teva continues to broaden availability of biosimilars in Europe reinforcing the Company's commitment to improving patient access to biologic medicines TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea®, in Europe further strengthening the Company's growing
- PRTeva to Present at the Goldman Sachs Global Healthcare ConferencePARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. The fireside chat will begin at 8:00 A.M. Eastern Time. To access live webcasts of the presentations, please visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. Archived versions of the webcasts will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days. About Teva Teva Pharmaceutical Indust
- INSIDERSEC Form 4 filed by Director Zaks Tal Zvi4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Satchi-Fainaro Ronit4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Nisen Perry4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Lieberman Gerald M4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Elstein Amir4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Crane Rosemary A4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Lichtenstein Chen4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Barer Sol J4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSEC Form 4 filed by Director Mignone Roberto4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- SECSEC Form 8-K filed by Teva Pharmaceutical Industries Limited8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
TEVA FAQ
6 questionsWhat does Teva Pharmaceutical Industries Limited do?
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology...Where does TEVA stock trade?
Teva Pharmaceutical Industries Limited (TEVA) is listed on NYSE.What sector and industry is TEVA in?
Teva Pharmaceutical Industries Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TEVA?
Teva Pharmaceutical Industries Limited has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $3500.00 price target on 2025-12-09. Recent price targets range from $1400.00 to $3500.00.What companies are similar to TEVA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TEVA side-by-side with any of them on Quantisnow.How can I track TEVA on Quantisnow?
Quantisnow aggregates Teva Pharmaceutical Industries Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TEVA to receive live email and push alerts on every new disclosure.